Bayer Animal Health GmbH and Mitsui Chemicals Agro, Inc., have signed a global license agreement to advance innovative parasiticides for companion animals based on MCAG’s innovation and technology.
As part of the license agreement, Bayer will develop and commercialize novel compounds based on intellectual property from MCAG. Further terms of the agreement were not disclosed.
Pet ownership is growing around the world and with that customers’ requirement for effective and convenient protection from parasites. “At Bayer, we passionately care for the health and well-being of animals,” said Dr. Dirk Ehle, Head of Bayer Animal Health. “And we have long been committed to help pet owners protect their animals from parasites. Today we have taken an important next step to further deliver on this commitment to our customers.”
Dr. Sabine Bongaerts, Head of Drug Discovery within Bayer Animal Health, added: “This license agreement combines the strong science base within Bayer with innovative chemistry from MCAG. It will enable us to further expand our strong portfolio of parasiticides in the companion animal sector and deliver new compelling products to our customers.”
Mr. Satoshi Ozawa, President and CEO of MCAG said: “Under the concept of Technology and Innovation, MCAG has been providing its innovative products and services to the customers in agrochemicals and environmental health businesses for many years so far. Now, through close and successful collaboration with Bayer in the animal health sector, we are excited about this new opportunity to have our innovation work for another horizon of companion animal business.”